SCHEMBL14839482

SCHEMBL14839482

CC(C)c1ccc(/C=C/C(O)c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
EGFR P00533 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
CYP1A2 P05177 1/20 0.43
TYR P14679 1/20 0.42
LMNA P02545 3/20 0.42
HTT P42858 2/20 0.42
PKM P14618 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14839481 0.95 EGFR (0.50) KDM4EMAPK1SMN1; SMN2NPC1POLB
SCHEMBL14839478 0.93 KDM4E (0.53) KDM4EMAPK1SMN1; SMN2NPC1POLB
SCHEMBL10411854 0.89 CYP1A2 (0.52) MAPK1CYP1A2LMNARARARARB
SCHEMBL477645 0.85 CYP1A2 (0.57) SMN1; SMN2CYP1A2LMNAMAPTALDH1A1
SCHEMBL477646 0.85 CYP1A2 (0.57) SMN1; SMN2CYP1A2LMNAMAPTALDH1A1
SCHEMBL477469 0.85 CYP1A2 (0.57) SMN1; SMN2CYP1A2LMNAMAPTALDH1A1
SCHEMBL477467 0.85 CYP1A2 (0.57) SMN1; SMN2CYP1A2LMNAMAPTALDH1A1
SCHEMBL4630868 0.84 CYP3A4 (0.51) RAB9AEGFRCYP1A2KMT2AMAPT
SCHEMBL4630867 0.84 CYP3A4 (0.51) RAB9AEGFRCYP1A2KMT2AMAPT
SCHEMBL28403553 0.81 ALOX15 (0.50) KDM4ESMN1; SMN2NPC1RAB9AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2775996-B1 USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS MERCK PATENT GMBH (DE) 2018-02-28 EP disclosed
US-20150051295-A1 USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS MERCK PATENT GMBH (DE) 2015-02-19 US disclosed
US-20150051295-A1 USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS MERCK PATENT GMBH (DE) 2015-02-19 US disclosed
WO-2013045098-A2 USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS MERCK PATENT GMBH (DE) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051295-A1 USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS GPX4, EBP, CAT KDM4E 3888/4885MAPK1 3467/4885SMN1; SMN2 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.